Clinical trial
Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00054535 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00054535 |
|---|---|
| Title | Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma |
| Official title | Treatment Of Patients With Metastatic Melanoma Using Recombinant Vaccinia And Fowlpox Viruses Encoding The Tyrosine Antigen In Combination With Interleukin-2 |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | aldesleukin, recombinant fowlpox-tyrosinase vaccine, vaccinia-tyrosinase vaccine |
| Start date | Jan 1, 2003 |
| Completion | Sep 1, 2004 |
| First posted | Feb 6, 2003 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: